HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

BioAge Labs, a clinical-stage biopharmaceutical company listed on NASDAQ (ticker: BIOA), has begun dosing the first participant in its Phase 2 trial for BGE-102, a novel oral inhibitor targeting the NLRP3 inflammasome pathway for cardiovascular risk reduction. This marks a key step in the clinical development of BGE-102, which aims to address unmet needs in cardiovascular disease treatment.

HitGen Inc., a company listed on the Shanghai Stock Exchange (ticker: 688222.SH), has a partnership with BioAge Labs and congratulates its partner on this milestone. The trial's initiation indicates progress in BioAge's pipeline of therapeutic candidates.

The Phase 2 trial will evaluate the safety, efficacy, and dosing of BGE-102 in patients at risk of cardiovascular events. The outcome of this trial could influence the future development and potential approval of the drug.

This development is relevant for investors and stakeholders in both BioAge Labs and HitGen, as successful trial results could lead to further clinical progress and commercial opportunities. The news reflects ongoing advancements in innovative treatments for cardiovascular diseases.